8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Mar 17, 2026·SEC
Mainz Biomed B.V.(MYNZ)Earnings, Financials & Key Ratios
MYNZ•NASDAQ
$0.70
$677764 mkt cap·Price updated Apr 24, 2026
AboutMainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.Show more
- Revenue$894K-0.2%
- EBITDA-$18M+31.0%
- Net Income-$22M+17.7%
- EPS (Diluted)-22.36-1280.2%
- Gross Margin64.31%+13.0%
- EBITDA Margin-1977.47%+30.9%
- Operating Margin-2091.23%+29.7%
- Net Margin-2421.8%+17.5%
- ROE-465.82%-53.6%
- ROIC-419.72%+60.3%
- Debt/Equity0.54-76.3%
- Interest Coverage-17.39+47.2%
MYNZ Key Insights
Mainz Biomed B.V. (MYNZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 26.0%
- ✓Share count reduced 94.0% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MYNZ Price & Volume
Mainz Biomed B.V. (MYNZ) stock price & volume — 10-year historical chart
Loading chart...
MYNZ Growth Metrics
Mainz Biomed B.V. (MYNZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years26.01%
3 Years15.69%
TTM45.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1156.11%
Return on Capital
10 Years-331.67%
5 Years-326.05%
3 Years-244.12%
Last Year-277.78%
MYNZ Peer Comparison
Mainz Biomed B.V. (MYNZ) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 GKOS | 7.85B | 134.15 | -40.90 | 32.33% | -34.34% | -26.46% | 0.21 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 SDGR | 992.29M | 13.28 | -9.42 | 23.29% | -40.6% | -30.85% | 0.30 | |
 GH | 12.1B | 92.26 | -27.79 | 32.88% | -40.1% | |||
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 | |
 CERS | 522.96M | 2.61 | -31.83 | 14.35% | -4.41% | -15.18% | 1.49 | |
 TMO | 176.36B | 474.56 | 26.75 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare MYNZ vs Peers
Mainz Biomed B.V. (MYNZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MYNZ Income Statement
Mainz Biomed B.V. (MYNZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 281.39K | 493.56K | 577.35K | 529.88K | 895.48K | 893.99K |
| Revenue Growth % | - | 75.4% | 16.98% | -8.22% | 69% | -0.17% |
| Cost of Goods Sold | 342.66K | 370.48K | 399.73K | 347.73K | 385.82K | 319.11K |
| COGS % of Revenue | 121.77% | 75.06% | 69.23% | 65.62% | 43.09% | 35.69% |
| Gross Profit | -61.27K▲ 0% | 123.08K▲ 300.9% | 177.62K▲ 44.3% | 182.15K▲ 2.5% | 509.66K▲ 179.8% | 574.88K▲ 12.8% |
| Gross Margin % | -21.77% | 24.94% | 30.77% | 34.38% | 56.91% | 64.31% |
| Gross Profit Growth % | - | 300.89% | 44.31% | 2.55% | 179.8% | 12.8% |
| Operating Expenses | 690.21K | 796.8K | 9.56M | 26.36M | 27.15M | 19.27M |
| OpEx % of Revenue | 245.28% | 161.44% | 1655.31% | 4974.16% | 3032.38% | 2155.54% |
| Selling, General & Admin | 570.25K | 458.37K | 9.41M | 22.81M | 17.22M | 12.77M |
| SG&A % of Revenue | 202.65% | 92.87% | 1630.05% | 4304.86% | 1923.17% | 1428.98% |
| Research & Development | 250.32K | 311.85K | 466.69K | 3.66M | 9.59M | 5.84M |
| R&D % of Revenue | 88.96% | 63.18% | 80.83% | 690.82% | 1070.98% | 653.14% |
| Other Operating Expenses | -130.35K | 26.57K | -320.89K | -114.05K | 342.4K | 656.34K |
| Operating Income | -921.91K▲ 0% | -766.09K▲ 16.9% | -9.72M▼ 1169.4% | -26.44M▼ 171.9% | -26.64M▼ 0.8% | -18.7M▲ 29.8% |
| Operating Margin % | -327.62% | -155.22% | -1684.36% | -4990.6% | -2975.47% | -2091.23% |
| Operating Income Growth % | - | 16.9% | -1169.38% | -171.93% | -0.76% | 29.83% |
| EBITDA | -868.87K | -613.25K | -9.65M | -25.98M | -25.61M | -17.68M |
| EBITDA Margin % | -308.77% | -124.25% | -1672.25% | -4903.9% | -2859.94% | -1977.47% |
| EBITDA Growth % | - | 29.42% | -1474.34% | -169.14% | 1.44% | 30.97% |
| D&A (Non-Cash Add-back) | 53.04K | 152.84K | 69.93K | 459.43K | 1.03M | 1.02M |
| EBIT | -755.12K | -410.48K | -11.35M | -26.1M | -26.05M | -20.58M |
| Net Interest Income | -201.94K | -268.79K | -339.17K | -289.32K | -809.58K | -1.08M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 201.94K | 268.79K | 339.17K | 289.32K | 809.58K | 1.08M |
| Other Income/Expense | -35.15K | 86.82K | -1.97M | 56.7K | 348.95K | -2.96M |
| Pretax Income | -957.05K▲ 0% | -586.89K▲ 38.7% | -11.7M▼ 1892.7% | -26.39M▼ 125.6% | -26.3M▲ 0.3% | -21.65M▲ 17.7% |
| Pretax Margin % | -340.11% | -118.91% | -2025.67% | -4979.9% | -2936.5% | -2421.8% |
| Income Tax | 0 | 0 | 377.12K | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -3.22% | 0% | 0% | 0% |
| Net Income | -957.05K▲ 0% | -586.89K▲ 38.7% | -11.69M▼ 1891.9% | -26.45M▼ 126.3% | -26.3M▲ 0.6% | -21.65M▲ 17.7% |
| Net Margin % | -340.11% | -118.91% | -2024.79% | -4992.24% | -2936.5% | -2421.8% |
| Net Income Growth % | - | 38.68% | -1891.86% | -126.28% | 0.59% | 17.66% |
| Net Income (Continuing) | -957.05K | -586.89K | -11.69M | -26.39M | -26.3M | -21.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10▲ 0% | -0.05▲ 49.9% | -1.67▼ 3233.3% | -1.87▼ 12.0% | -1.62▲ 13.4% | -22.36▼ 1280.2% |
| EPS Growth % | - | 49.9% | -3233.33% | -11.98% | 13.37% | -1280.25% |
| EPS (Basic) | -0.10 | -0.05 | -1.67 | -1.87 | -1.62 | -22.36 |
| Diluted Shares Outstanding | 11.71M | 5.61M | 7.21M | 14.16M | 16.24M | 968.23K |
| Basic Shares Outstanding | 11.71M | 5.61M | 7.21M | 14.16M | 16.24M | 968.23K |
| Dividend Payout Ratio | - | - | - | - | - | - |
MYNZ Balance Sheet
Mainz Biomed B.V. (MYNZ) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|
| Total Current Assets | 260.01K | 186.4K | 9.61M | 18.38M | 8.98M | 7.84M |
| Cash & Short-Term Investments | 203.59K | 122.57K | 8.73M | 17.14M | 7.07M | 6.24M |
| Cash Only | 203.59K | 122.57K | 8.73M | 17.14M | 7.07M | 6.24M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 40.8K | 44.24K | 17.76K | 259.14K | 354.51K | 213.75K |
| Days Sales Outstanding | 52.92 | 32.72 | 11.23 | 178.5 | 144.5 | 87.27 |
| Inventory | 0 | 0 | 0 | 175.47K | 613.64K | 372.87K |
| Days Inventory Outstanding | - | - | - | 184.19 | 580.52 | 426.49 |
| Other Current Assets | 0 | 0 | 0 | 0 | 135.06K | 127.29K |
| Total Non-Current Assets | 455.95K | 486.87K | 431.59K | 1.86M | 6.43M | 5.39M |
| Property, Plant & Equipment | 455.95K | 486.87K | 431.59K | 1.84M | 3.03M | 2.38M |
| Fixed Asset Turnover | 0.62x | 1.01x | 1.34x | 0.29x | 0.30x | 0.38x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 3.39M | 3.02M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 23.27K | 108 | 0 |
| Total Assets | 715.96K▲ 0% | 673.27K▼ 6.0% | 10.04M▲ 1391.3% | 20.24M▲ 101.6% | 15.41M▼ 23.9% | 13.24M▼ 14.1% |
| Asset Turnover | 0.39x | 0.73x | 0.06x | 0.03x | 0.06x | 0.07x |
| Asset Growth % | - | -5.96% | 1391.35% | 101.59% | -23.87% | -14.09% |
| Total Current Liabilities | 459.71K | 701.95K | 1.35M | 4.24M | 9.24M | 5.95M |
| Accounts Payable | 200.06K | 195.41K | 832.52K | 1.33M | 2.33M | 1.25M |
| Days Payables Outstanding | 213.1 | 192.52 | 760.19 | 1.4K | 2.2K | 1.43K |
| Short-Term Debt | 173.66K | 219.02K | 193.43K | 1.04M | 4.94M | 2.13M |
| Deferred Revenue (Current) | 2.5K | 1.51K | 0 | 199.41K | 138.89K | 0 |
| Other Current Liabilities | 0 | 98.16K | -3.22K | 0 | 388.84K | 690.58K |
| Current Ratio | 0.57x | 0.27x | 7.11x | 4.33x | 0.97x | 1.32x |
| Quick Ratio | 0.57x | 0.27x | 7.11x | 4.29x | 0.91x | 1.26x |
| Cash Conversion Cycle | - | - | - | -1.04K | -1.48K | -920.79 |
| Total Non-Current Liabilities | 2.21M | 2.71M | 2.33M | 1.9M | 2.92M | 1.24M |
| Long-Term Debt | 1.79M | 2.27M | 1.94M | 943.21K | 1.03M | 0 |
| Capital Lease Obligations | 418.14K | 447.44K | 387.77K | 959.12K | 1.17M | 865.98K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 726.98K | 376.1K |
| Total Liabilities | 2.67M | 3.41M | 3.68M | 6.14M | 12.16M | 7.19M |
| Total Debt | 2.41M | 2.98M | 2.58M | 3.23M | 7.42M | 3.27M |
| Net Debt | 2.21M | 2.86M | -6.15M | -13.91M | 349.86K | -2.96M |
| Debt / Equity | - | - | 0.41x | 0.23x | 2.28x | 0.54x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -4.57x | -2.85x | -28.67x | -91.40x | -32.91x | -17.39x |
| Total Equity | -1.95M▲ 0% | -2.74M▼ 40.6% | 6.36M▲ 332.0% | 14.1M▲ 121.6% | 3.25M▼ 76.9% | 6.05M▲ 86.1% |
| Equity Growth % | - | -40.57% | 332.03% | 121.6% | -76.95% | 86.09% |
| Book Value per Share | -0.17 | -0.49 | 0.88 | 1.00 | 0.20 | 6.24 |
| Total Shareholders' Equity | -1.95M | -2.74M | 6.36M | 14.1M | 3.25M | 6.05M |
| Common Stock | 106.11K | 64.27K | 141.07K | 164.9K | 235.82K | 922.13K |
| Retained Earnings | -4.37M | -4.95M | -16.64M | -43.03M | -69.33M | -90.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.31M | 2.11M | 9.74M | 18.13M | 20.83M | 27.04M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
MYNZ Cash Flow Statement
Mainz Biomed B.V. (MYNZ) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|
| Cash from Operations | -416.5K | -468.74K | -3.22M | -14.77M | -21.94M | -17.09M |
| Operating CF Margin % | -148.01% | -94.97% | -557.78% | -2787.36% | -2449.96% | -1911.65% |
| Operating CF Growth % | - | -12.54% | -587.02% | -358.64% | -48.54% | 22.1% |
| Net Income | -957.05K | -586.89K | -11.69M | -26.39M | -26.3M | -21.65M |
| Depreciation & Amortization | 53.04K | 60.46K | 69.93K | 379.8K | 866.41K | 1.02M |
| Stock-Based Compensation | 0 | 0 | 6.43M | 9.82M | 4.01M | 1.14M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 64.48K | 107 | 2.11M | 1.85M | -450.53K | 2.36M |
| Working Capital Changes | 423.04K | 57.59K | -138.62K | -437.4K | -64.63K | 51.75K |
| Change in Receivables | 339.62K | -99.15K | 24.21K | -211.23K | 15.54K | 64.28K |
| Change in Inventory | 0 | -160.48K | -670.73M | -172.38K | -500.19K | 29.81K |
| Change in Payables | 0 | 160.48K | 670.73M | 0 | 720.24K | 84.61K |
| Cash from Investing | 0 | -9.69K | 1.2M | -658.48K | -1.9M | -198.82K |
| Capital Expenditures | 0 | -9.69K | -16.7K | -658.48K | -1.2M | -104.95K |
| CapEx % of Revenue | - | 1.96% | 2.89% | 124.27% | 133.88% | 11.74% |
| Acquisitions | 0 | 0 | 1.22M | 0 | 0 | 32.78K |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -700K | -126.65K |
| Cash from Financing | 424K | 396.68K | 10.61M | 23.94M | 14.23M | 16.6M |
| Debt Issued (Net) | 424K | -2.13K | 185.37K | -197.94K | 7.83M | 2.83M |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 398.81K | 0 | -107.03K | 0 | 0 |
| Net Change in Cash | -25.94K▲ 0% | -81.02K▼ 212.3% | 8.6M▲ 10720.8% | 8.41M▼ 2.2% | -10.07M▼ 219.7% | -835.25K▲ 91.7% |
| Free Cash Flow | -416.5K▲ 0% | -478.42K▼ 14.9% | -3.24M▼ 576.6% | -15.43M▼ 376.6% | -23.84M▼ 54.5% | -17.34M▲ 27.2% |
| FCF Margin % | -148.01% | -96.93% | -560.67% | -2911.63% | -2662% | -1940.17% |
| FCF Growth % | - | -14.87% | -576.61% | -376.61% | -54.51% | 27.24% |
| FCF per Share | -0.04 | -0.09 | -0.45 | -1.09 | -1.47 | -17.91 |
| FCF Conversion (FCF/Net Income) | 0.44x | 0.80x | 0.28x | 0.56x | 0.83x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 125.54K | 0 | 198.06K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
MYNZ Key Ratios
Mainz Biomed B.V. (MYNZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -645.93% | -258.62% | -303.2% | -465.82% |
| Return on Invested Capital (ROIC) | - | -306.19% | -4482.93% | -10104.56% | -1056.87% | -419.72% |
| Gross Margin | -21.77% | 24.94% | 30.77% | 34.38% | 56.91% | 64.31% |
| Net Margin | -340.11% | -118.91% | -2024.79% | -4992.24% | -2936.5% | -2421.8% |
| Debt / Equity | - | - | 0.41x | 0.23x | 2.28x | 0.54x |
| Interest Coverage | -4.57x | -2.85x | -28.67x | -91.40x | -32.91x | -17.39x |
| FCF Conversion | 0.44x | 0.80x | 0.28x | 0.56x | 0.83x | 0.79x |
| Revenue Growth | - | 75.4% | 16.98% | -8.22% | 69% | -0.17% |
MYNZ SEC Filings & Documents
Mainz Biomed B.V. (MYNZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
10-K Annual Reports
1FY 2026
Mar 31, 2026·SEC
MYNZ Frequently Asked Questions
Mainz Biomed B.V. (MYNZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mainz Biomed B.V. (MYNZ) reported $1.6M in revenue for fiscal year 2024. This represents a 472% increase from $0.3M in 2019.
Mainz Biomed B.V. (MYNZ) saw revenue decline by 0.2% over the past year.
Mainz Biomed B.V. (MYNZ) reported a net loss of $40.1M for fiscal year 2024.
Dividend & Returns
Mainz Biomed B.V. (MYNZ) has a return on equity (ROE) of -465.8%. Negative ROE indicates the company is unprofitable.
Mainz Biomed B.V. (MYNZ) had negative free cash flow of $27.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More MYNZ
Mainz Biomed B.V. (MYNZ) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates